Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001641172-25-024575
Filing Date
2025-08-18
Accepted
2025-08-18 14:56:44
Documents
1
Period of Report
2025-08-15

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 4288
  Complete submission text file 0001641172-25-024575.txt   5882
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Issuer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 95091 RPO KINGSGATE VANCOUVER CANADA British Columbia, Canada V5T 4T8
Business Address
Holloway Michael Andrew (Reporting) CIK: 0002076371 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39717 | Film No.: 251227575